Founder and CEO
Harvard Univeristy and Yale Law Scool
Vivek Ramaswamy, founded Roivant sciences in 2014, and since then the investment strategy he has adopted in his company involves a financially innovative approach: developing drugs, often by purchasing those which have been forgotten or abandoned by the pharmaceutical industry.
In 2016, Vivek Ramaswamy is disrupting the biotech business through drug development deals and plans. He is well known for the biggest biotechnology public offering of 2016; 218 million dollars were raised for Myovant Sciences and its shares listed on Nasdaq in October. In April he formed the company and struck a deal with Takeda Pharmaceuticals for a prostate cancer drug and a female infertility drug. Furthermore, in the US, Ramaswamy was able to follow through the biggest IPO in the biotech history by listing shares of Axovant, a company aiming to develop a new Alzheimer’s drug. In 2015, the initial public offering for Roivant subsidiary Axovant raised 360 million dollars.
Roivant Sciences is backed by the QVT hedge fund, in conjunction with an Israeli drug maker. In 2016, Roivant disclosed a major investment from billionaire Andreas Halvorsen’s Viking Global Investors hedge fund. Ramaswamy himself was also a partner of QVT in his prior career.
Mr Ramaswamy has also co-founded and served as President of Campus venture Network, a technology company, he has worked at QVT Financial, where he served as partner and co-managed the firm’s biotech portfolio. Currently, Ramaswamy serves on the Board of Directors of Sumitovant Biopharma. Sumitovant is the result of a 3-billion-dollar transaction in 2019. It transferred ownership stakes in 5 companies in the Roivant family and includes investigational medicines which generated 4 successful Phase 3 studies in 2019.
This interview is exclusively open to LSE students.